Discover Danaher: Idea
Discover Danaher
As a leading global life sciences and diagnostics innovator, Danaher is helping to solve health challenges impacting patients around the world. We seek out the most important problems in biomedicine – those with the potential for high value and high impact – as well as collaborators who can take them on with us hand-in-hand.
A critical part of our strategy is our Beacons program, which invests in partnerships with leading academic researchers such as Jennifer Doudna, Carl June, Howard Chang, and others. Beacons are a unique mechanism for accelerating novel ideas from proof-of-concept, to product, to patient.
Danaher Beacons
Our current Beacons are focused on genomic medicines, precision diagnostics, next-generation biomanufacturing, human systems, and data science – all complex fields with significant opportunities to fuel new workflow and product development. In each Beacon, we learn from our partners’ groundbreaking science, and they see what it takes to develop products with the potential to drive transformational change.
Brain injury diagnostics
This collaboration aims to develop new, more sensitive methods for diagnosing mild traumatic brain injury (TBI). The tests will leverage highly sensitive clinical immunoassay technology to evaluate the efficacy of a new biomarker panel intended to help doctors diagnose mild TBI earlier and more precisely. If effective, the approach could also someday be adapted for the diagnosis of other types of brain injury or neurodegenerative diseases.
Next-gen toxicity testing
This collaboration aims to improve patient safety and accelerate the development of new therapies by addressing a leading cause of failure in clinical trials. The goal is to develop more streamlined, scalable, and genetically diverse liver organoid technology as a drug toxicity screening solution, so that the biopharma industry is better-positioned be able to deliver better, safer drugs to patients faster.
Sepsis subtyping innovation
This partnership is developing a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year. The test will leverage rapid molecular diagnostic technologies to pinpoint different subtypes of sepsis and allow the development of novel personalized care paths, including which targeted therapies are most likely to help.